Literature DB >> 22124306

BPH: unmet needs in managing LUTS--a European perspective.

Cosimo De Nunzio, Andrea Tubaro.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 22124306     DOI： 10.1038/nrurol.2011.190

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  9 in total

1.  Update on AUA guideline on the management of benign prostatic hyperplasia.

Authors:  Kevin T McVary; Claus G Roehrborn; Andrew L Avins; Michael J Barry; Reginald C Bruskewitz; Robert F Donnell; Harris E Foster; Chris M Gonzalez; Steven A Kaplan; David F Penson; James C Ulchaker; John T Wei
Journal:  J Urol       Date:  2011-03-21       Impact factor: 7.450

2.  Benign prostatic hyperplasia evaluation and management by urologists and primary care physicians: practice patterns from the observational BPH registry.

Authors:  John T Wei; Martin M Miner; William D Steers; Raymond C Rosen; Allen D Seftel; David J Pasta; Wendy J Carman; Claus G Roehrborn
Journal:  J Urol       Date:  2011-07-24       Impact factor: 7.450

3.  High prevalence of benign prostatic hypertrophy in the community.

Authors:  W M Garraway; G N Collins; R J Lee
Journal:  Lancet       Date:  1991-08-24       Impact factor: 79.321

4.  A widespread population study of actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia across Europe and beyond official clinical guidelines.

Authors:  Jean-Nicolas Cornu; Olivier Cussenot; François Haab; Bertrand Lukacs
Journal:  Eur Urol       Date:  2010-06-09       Impact factor: 20.096

5.  Medical consumption and costs during a one-year follow-up of patients with LUTS suggestive of BPH in six european countries: report of the TRIUMPH study.

Authors:  N J A van Exel; M A Koopmanschap; J McDonnell; C R Chapple; R Berges; F F H Rutten
Journal:  Eur Urol       Date:  2005-11-02       Impact factor: 20.096

6.  Profile and management of patients treated for the first time for lower urinary tract symptoms/benign prostatic hyperplasia in four European countries.

Authors:  Richard-Olivier Fourcade; Nathalie Théret; Charles Taïeb
Journal:  BJU Int       Date:  2008-02-15       Impact factor: 5.588

7.  Gender and age differences in the perception of bother and health care seeking for lower urinary tract symptoms: results from the hospitalised and outpatients' profile and expectations study.

Authors:  Apostolos Apostolidis; Paraskevi-Sofia Kirana; Gretchen Chiu; Carol Link; Marina Tsiouprou; Dimitrios Hatzichristou
Journal:  Eur Urol       Date:  2009-08-12       Impact factor: 20.096

8.  Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7).

Authors:  Raymond Rosen; Jens Altwein; Peter Boyle; Roger S Kirby; B Lukacs; Eric Meuleman; Michael P O'Leary; Paolo Puppo; Chris Robertson; Francois Giuliano
Journal:  Eur Urol       Date:  2003-12       Impact factor: 20.096

9.  Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia.

Authors:  Richard-Olivier Fourcade; François Lacoin; Morgan Rouprêt; Alain Slama; Camille Le Fur; Emilie Michel; Axel Sitbon; François-Emery Cotté
Journal:  World J Urol       Date:  2011-09-03       Impact factor: 4.226
  9 in total
  2 in total

1.  Patient's adherence on pharmacological therapy for benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) is different: is combination therapy better than monotherapy?

Authors:  Luca Cindolo; Luisella Pirozzi; Petros Sountoulides; Caterina Fanizza; Marilena Romero; Pietro Castellan; Alessandro Antonelli; Claudio Simeone; Andrea Tubaro; Cosimo de Nunzio; Luigi Schips
Journal:  BMC Urol       Date:  2015-09-21       Impact factor: 2.264

2.  Factors associated with quality of life in patients with benign prostatic hyperplasia, 2009-2016.

Authors:  Sewon Park; Kyu-Sung Lee; Mankyu Choi; Munjae Lee
Journal:  Medicine (Baltimore)       Date:  2022-09-09       Impact factor: 1.817
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.